Loading...
XCNQ
PREV
Market cap6mUSD
Jul 09, Last price  
0.02CAD
1D
0.00%
1Q
-25.00%
IPO
-80.77%
Name

Preveceutical Medical Inc

Chart & Performance

D1W1MN
XCNQ:PREV chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
4.54%
Rev. gr., 5y
-12.64%
Revenues
0k
031,05422,23415,4523,031000000
Net income
-2m
L+134,849.91%
-62,451-3,127,217-7,231,885-11,884,130-3,578,900-3,801,118-1,726,571-1,481,370-1,274,471-1,174-1,584,312
CFO
-2m
L+303.07%
-13,371-1,315,332-4,299,038-7,573,030-993,93664,595-426,390-222,644-296,974-426,693-1,719,883

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid Sol-Gel Delivery system, a cannabinoid-based technology designed for nose-to-brain delivery, aiming to alleviate symptoms associated with pain, inflammation, epileptic seizures, and diverse neurological conditions. Also in development is the BSV Peptide Program, which focuses on hindering cancer's advancement, alongside a non-addictive analgesic for effective pain relief. The company is also progressing with a Dual Gene Therapy project to address type 2 diabetes and obesity. Complementing these initiatives, PreveCeutical is involved in the creation of various products derived from medicinal cannabis. The company is headquartered in Vancouver, Canada.
IPO date
Dec 30, 2016
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT